Home > Publications database > SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model |
Journal Article | PUBDB-2021-04550 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2021
Moses King
Cambridge, Mass.
This record in other databases:
Please use a persistent id in citations: doi:10.1126/science.abf1611 doi:10.3204/PUBDB-2021-04550
Abstract: Vaccines are an important tool in the fight against COVID-19, but developing antiviral drugs is also a high priority, especially with the rise of variants that may partially evade vaccines. The viral protein main protease is required for cleaving precursor polyproteins into functional viral proteins. This essential function makes it a key drug target. Qiao et al. designed 32 inhibitors based on either boceprevir or telaprevir, both of which are protease inhibitors approved to treat hepatitis C virus. Six compounds protected cells from viral infection with high potency, and two of these were selected for in vivo studies based on pharmokinetic experiments. Both showed strong antiviral activity in a mouse model.
![]() |
The record appears in these collections: |